# Venetoclax, Azacitidine, and Lintuzumab-Ac225 in AML Patients

> **NCT03932318** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Actinium Pharmaceuticals**

## Conditions studied

- Acute Myeloid Leukemia
- Relapsed Adult AML

## Interventions

- **BIOLOGICAL:** Lintuzumab-Ac225
- **DRUG:** Venetoclax
- **DRUG:** Azacitidine

## Key facts

- **NCT ID:** NCT03932318
- **Lead sponsor:** Actinium Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-03
- **Primary completion:** 2023-12
- **Final completion:** 2024-09
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** study postponed
- **Last updated:** 2023-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03932318

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03932318, "Venetoclax, Azacitidine, and Lintuzumab-Ac225 in AML Patients". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT03932318. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*